Tumor biology in older breast cancer patients - What is the impact on survival stratified for guideline adherence? A retrospective multicentre cohort study of 5378 patients

Publikationstyp:
Zeitschriftenaufsatz
Metadaten:
Autoren
  • Florian Ebner
  • Reyn van Ewijk
  • Achim Woeckel
  • Katharina Hancke
  • Lukas Schwentner
  • Visnja Fink
  • Rolf Kreienberg
  • Wolfgang Janni
  • Maria Blettner
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000353624600014&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.breast.2015.02.029
eISSN
1532-3080
Externe Identifier
  • Clarivate Analytics Document Solution ID: CG9HC
  • PubMed Identifier: 25769974
ISSN
0960-9776
Ausgabe der Veröffentlichung
3
Zeitschrift
BREAST
Schlüsselwörter
  • Breast cancer
  • Guideline
  • Survival
  • Older
  • Elderly
Paginierung
256 - 262
Datum der Veröffentlichung
2015
Status
Published
Titel
Tumor biology in older breast cancer patients - What is the impact on survival stratified for guideline adherence? A retrospective multicentre cohort study of 5378 patients
Sub types
  • Article
Ausgabe der Zeitschrift
24

Datenquelle: Web of Science (Lite)

Andere Metadatenquellen:
Autoren
  • Florian Ebner
  • Reyn van Ewijk
  • Achim Wöckel
  • Katharina Hancke
  • Lukas Schwentner
  • Visnja Fink
  • Rolf Kreienberg
  • Wolfgang Janni
  • Maria Blettner
DOI
10.1016/j.breast.2015.02.029
ISSN
0960-9776
Ausgabe der Veröffentlichung
3
Zeitschrift
The Breast
Sprache
en
Paginierung
256 - 262
Datum der Veröffentlichung
2015
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.breast.2015.02.029
Datum der Datenerfassung
2024
Titel
Tumor biology in older breast cancer patients – What is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients
Ausgabe der Zeitschrift
24

Datenquelle: Crossref

Abstract
<h4>Purpose</h4>The tumor biology of older breast cancer patients (oBCP) is usually less aggressive, however applied adjuvant treatment is often less potent resulting in an impaired disease free survival and overall survival in this group. This study tries to answer the following questions for the biological subtypes of oBCP (70+ y):<h4>Methods</h4>Between 1992 and 2008 the BRENDA ('BRENDA' = quality of BREast caNcer care unDer evidence-bAsed guidelines) study group recorded medical data of 17 participating certified breast cancer centers in Germany. We performed a retrospective multi-center database analysis of 5632 patient records. Guideline-adherent-treatment (GL+) of oBCP(n = 1918) was compared to GL+ of yBCP(n = 3714).<h4>Results</h4>OBCP were more likely to have hormone receptor positive (HR+) and HER2neu negative (HER2-) breast cancer (77.5% vs 74.5%). The rate of GL- was significantly different (p < 0.001) between the age groups and the biological subgroups (yBCP vs oBCP: 21.8%vs38.8% (HR+/HER2-); 30.6%vs49.7% (HR+/HER2+); 23.6%vs69.5% (HR-/HER2+); 31.4%vs67.8% (TNBC)). The survival parameters for HR+/HER2- and TNBC were significantly worse in case of GL- regarding chemotherapy, and if applicable endocrine therapy. A similar association only existed in HR-/HER2+ tumors for GL- for radiotherapy and in HR+/HER2+ tumors for chemotherapy.<h4>Conclusions</h4>Beside the significantly different distribution of biological subtypes in the age groups there is an association between biological subtype, and GL+ influencing survival parameters in oBCP.
Addresses
  • Universität Ulm, Klinik für Frauenheilkunde und Geburtshilfe, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: florian.ebner@uniklinik-ulm.de.
Autoren
  • Florian Ebner
  • Reyn van Ewijk
  • Achim Wöckel
  • Katharina Hancke
  • Lukas Schwentner
  • Visnja Fink
  • Rolf Kreienberg
  • Wolfgang Janni
  • Maria Blettner
DOI
10.1016/j.breast.2015.02.029
eISSN
1532-3080
Externe Identifier
  • PubMed Identifier: 25769974
Funding acknowledgements
  • Bundesministerium für Bildung und Forschung: BMBF-Grant- 01ZP0505
Open access
false
ISSN
0960-9776
Ausgabe der Veröffentlichung
3
Zeitschrift
Breast (Edinburgh, Scotland)
Schlüsselwörter
  • Humans
  • Breast Neoplasms
  • Neoplasm Recurrence, Local
  • Receptor, erbB-2
  • Antineoplastic Combined Chemotherapy Protocols
  • Treatment Outcome
  • Chemotherapy, Adjuvant
  • Survival Analysis
  • Retrospective Studies
  • Aged
  • Middle Aged
  • Guideline Adherence
  • Germany
  • Female
  • Health Impact Assessment
Sprache
eng
Medium
Print-Electronic
Online publication date
2015
Paginierung
256 - 262
Datum der Veröffentlichung
2015
Status
Published
Datum der Datenerfassung
2015
Titel
Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients.
Sub types
  • Research Support, Non-U.S. Gov't
  • Multicenter Study
  • Journal Article
Ausgabe der Zeitschrift
24

Datenquelle: Europe PubMed Central

Abstract
PURPOSE: The tumor biology of older breast cancer patients (oBCP) is usually less aggressive, however applied adjuvant treatment is often less potent resulting in an impaired disease free survival and overall survival in this group. This study tries to answer the following questions for the biological subtypes of oBCP (70+ y): METHODS: Between 1992 and 2008 the BRENDA ('BRENDA' = quality of BREast caNcer care unDer evidence-bAsed guidelines) study group recorded medical data of 17 participating certified breast cancer centers in Germany. We performed a retrospective multi-center database analysis of 5632 patient records. Guideline-adherent-treatment (GL+) of oBCP(n = 1918) was compared to GL+ of yBCP(n = 3714). RESULTS: OBCP were more likely to have hormone receptor positive (HR+) and HER2neu negative (HER2-) breast cancer (77.5% vs 74.5%). The rate of GL- was significantly different (p < 0.001) between the age groups and the biological subgroups (yBCP vs oBCP: 21.8%vs38.8% (HR+/HER2-); 30.6%vs49.7% (HR+/HER2+); 23.6%vs69.5% (HR-/HER2+); 31.4%vs67.8% (TNBC)). The survival parameters for HR+/HER2- and TNBC were significantly worse in case of GL- regarding chemotherapy, and if applicable endocrine therapy. A similar association only existed in HR-/HER2+ tumors for GL- for radiotherapy and in HR+/HER2+ tumors for chemotherapy. CONCLUSIONS: Beside the significantly different distribution of biological subtypes in the age groups there is an association between biological subtype, and GL+ influencing survival parameters in oBCP.
Date of acceptance
2015
Autoren
  • Florian Ebner
  • Reyn van Ewijk
  • Achim Wöckel
  • Katharina Hancke
  • Lukas Schwentner
  • Visnja Fink
  • Rolf Kreienberg
  • Wolfgang Janni
  • Maria Blettner
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/25769974
DOI
10.1016/j.breast.2015.02.029
eISSN
1532-3080
Ausgabe der Veröffentlichung
3
Zeitschrift
Breast
Schlüsselwörter
  • Breast cancer
  • Elderly
  • Guideline
  • Older
  • Survival
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Female
  • Germany
  • Guideline Adherence
  • Health Impact Assessment
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Receptor, ErbB-2
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome
Sprache
eng
Country
Netherlands
Paginierung
256 - 262
PII
S0960-9776(15)00055-7
Datum der Veröffentlichung
2015
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2016
Titel
Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients.
Sub types
  • Journal Article
  • Multicenter Study
  • Research Support, Non-U.S. Gov't
Ausgabe der Zeitschrift
24

Datenquelle: PubMed

Beziehungen:
Eigentum von

Werkzeuge